AbstractSwitch from tamoxifen to anastrozole improves outcomes in early breast cancerPostmenopausal women who have taken tamoxifen for two years as adjuvant therapy are less likely to experience a recurrence of breast cancer and have improved overall survival if they switch to anastrozole compared with continuing to receive tamoxifen, according to the results of the ARNO 95 trial.1 This open‐label trial randomised post menopausal women who had undergone primary surgery for oestrogen receptor‐positive early breast cancer and had received two years of continuous tamoxifen therapy (20 or 30mg/day) to treatment with anastrozole (1mg/day; n=489) or to continue with tamoxifen (20 or 30mg/day; n=490) for an additional three years. The primary endpoint of the study was disease‐free survival (including local or distant recurrence, new contralateral breast cancer, or death); secondary end‐points included overall survival and toxicity. Disease‐free survival was improved in women who switched to anastrozole compared with those who continued with tamoxifen (HR 0.66; 95% CI 0.44‐1.00; P=0.049). Estimated three‐year disease‐free survival rates were 93.5% for anastrozole and 89.3% for tamoxifen. Switching to anastrozole was associated with improved overall survival compared with continuing on tamoxifen (HR 0.53; 95% CI 0.28‐0.99; P=0.045). Fewer patients who switched to anastrozole reported serious adverse events (22.7 vs 30.8%) compared with those who continued on tamoxifen, mainly because more patients in the tamoxifen group had endometrial events (OR 0.66; 95% CI 0.49‐0.89; P=0.0065). The authors conclude that patients switched to anastrozole after an initial period of tamoxifen therapy experience significant improvements in terms of disease‐free and overall survival. The results provide additional evidence that five years of tamoxifen is no longer the optimum adjuvant therapy for postmenopausal women with hormone‐receptor‐positive early breast cancer. 1. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2 years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol, published early online, 11 June 2007; doi: 10.1200/JCO.2006.08.8054.BASHH 10th annual NCCG conferenceThe 10th annual conference for nonconsultant career grade doctors in genitourinary medicine will be held at Loughborough University on 14 and 15 September 2007.The provisional programme includes: What's new in NSU? Prostatitis Sexual behaviour in MSM: emerging issues HPV vaccines Topical issues in O&G Post‐exposure prophylaxis. Further details are available on the BASHH website: www.bashh.org/committees/nccg/index.asp Copyright © 2007 Wiley Interface Ltd.